The most significant clinical data for retatrutide to date come from a Phase 2 randomised, double-blind, placebo-controlled trial published in The New England Journal of Medicine in 2023
Commonly associated with increased sweating during exercise.
The temporal association between drug administration and symptom onset, along with the exclusion of other potential causessuch as trauma, current infections, electrolyte disturbances, and drug abusestrongly supports this link
However, emerging therapeutic technologies, such as gene therapy , may improve the outlook for anemia in the near future (Payen 2012
Many weight-loss medications in the past offered only modest results, but semaglutide has been shown to help people lose a significant amount of weight